Voluntary recall issued for eye drops sold nationwide
Several over-the-counter eye products used to treat dry and irritated eyes have been voluntarily recalled following an audit by the U.S. Food and Drug Administration.
AvKARE, a pharmaceutical distributor, issued a voluntary recall notice on its website, noting that the products are being recalled due to "manufacturing deviations" found during the FDA audit.
According to the recall notice, the exact health dangers for consumers using the recalled products are unknown, but the company said "deviations may lead to products of unacceptable quality, and it is not possible to rule out patient risks resulting from use of these products."
ABC News has reached out to AvKARE for further information.
Here is what to know about the products being recalled and what consumers can do.
Both the FDA and AvKARE have detailed information on their websites about the products being voluntarily recalled.
The FDA's website also lists the number of cases involved in the recall:
13,872 cases of Artificial Tears Ophthalmic Solution (National Drug Code: 50268-043-15)
1,610 cases of Carboxymethylcellulose Sodium Ophthalmic Gel 1% (National Drug Code: 50268-066-15)
32,876 cases of Carboxymethylcellulose Sodium Ophthalmic Solution (National Drug Code: 50268-068-15)
13,104 cases of Lubricant Eye Drops Solution (National Drug Code: 50268-126-15)
14,333 cases of Polyvinyl Alcohol Ophthalmic Solution (National Drug Code: 50268-678-15)
The recalled items were first shipped between May 26, 2023, and April 21, 2025, according to AvKARE.
Mom helps save daughter's vision by noticing cloudiness in her eyes while breastfeeding
Expiration dates range from April 2025 to March 2027. Click here or here for a full list of expiration dates, lot codes and other product details.
AvKARE is advising consumers to discontinue use of the recalled products immediately.
Eye drops sold at stores including CVS, Rite Aid and Target could cause blindness, FDA warns
Yes, according to AvKARE.
The company is asking consumers to fill out a recall form on its website and fax the completed form to 931-292-6229 or email it to customerservice@avkare.com.
Once the form is received, the company will send consumers a Return Authorization Form to ship the product back to AvKARE.
The company says it will issue full credit, including shipping cost, for any returns.
Voluntary recall issued for eye drops sold nationwide originally appeared on goodmorningamerica.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Chocolate company recalls product nationwide for undeclared allergen
NEW YORK (PIX11) — Chocolate products have been recalled nationwide due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. The Pennsylvania-based distributor, Weaver Nut Company, Inc., has recalled its semi-sweet chocolate nonpareils with white or Christmas colored seeds, the advisory from the FDA says. More Local News People who have an allergy or severe sensitivity to milk could face serious or life-threatening allergic reactions if they consume the impacted products, the FDA warns. So far no illnesses have been reported. The issue was discovered through a wholesale customer who filed a complaint saying the shipment was misaligned with the product specifications. Lab tests confirmed the presence of milk in the product. More: Latest News from Around the Tri-State Consumers who have purchased the recalled product are urged not to eat it if they have a milk allergy and return it to the place of purchase for a full refund. Below is the list of lot codes for the affected chocolates. 47518 – Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) 204206 204207 204208 204209 204212 224225 D2645 – Nonpareils, Semi-Sweet Chocolate (White Seeds) 204214-RL 204214 204215 224221 224222 224223 135215 135216 135217 135220 135221 145204 145205-1 145207-1 145210-1 Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
CBS News
17 hours ago
- CBS News
Weaver Nut Company recalls chocolate nonpareils over undeclared milk allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. Recalled chocolate nonpareils. FDA Recalled chocolate nonpareils. FDA 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds) Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk.
Yahoo
21 hours ago
- Yahoo
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
Investing in biotech penny stocks is fraught with volatility, regulatory hurdles, and uncertain clinical results. Penny stocks are companies that trade for less than $5 per share. However, for those with a high risk tolerance, these small-cap stocks can provide outsized returns, particularly when scientific breakthroughs or U.S. Food and Drug Administration (FDA) approvals result in explosive gains. With Wall Street analysts issuing 'Strong Buy' ratings on these two high-potential plays, let's dig in to see whether these growth stocks could deliver on their promises. With a market capitalization of $21 million, Ovid Therapeutics is a small clinical-stage biopharmaceutical company focused on developing treatments for rare neurological disorders. Ovid's business model is centered on central nervous system (CNS) disorders, which are a challenging therapeutic area. Its pipeline includes novel compounds in early- to mid-stage development that target epilepsy and other genetically based neurological disorders. OVID stock has fallen 67.6% year-to-date (YTD), compared to the S&P 500 Index's ($SPX) gain of 1.6%. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Ovid currently has no FDA-approved products on the market. However, Wall Street analysts have called OVID a "Strong Buy," with all six analysts covering the stock rating it as such. Still, the company has also received a delisting notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share. Ovid has until Aug. 11, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days. Ovid's pipeline is small in size but very targeted. The most closely watched candidate is OV329, a highly selective small-molecule inhibitor of GABA aminotransferase (GABA-AT). OV329 is intended to treat epilepsy that has not responded to previous treatments. In preclinical models, the candidate has shown promise in controlling seizures while causing fewer side effects than existing treatments such as vigabatrin. Ovid Therapeutics anticipates Phase 1 trial results in the third quarter of 2025. The company has a good chance of its stock ticking upwards if the Phase 1 topline results for OV329 turn out positive. Ovid's other candidate is OV350, a next-generation KCC2 modulator that is also being tested in a Phase 1 trial. The company generated $130,000 in revenue from royalty agreements during Q1. At the end of the quarter, its cash, equivalents, and marketable securities totaled $43 million. This gives the company an estimated runway through the second half of 2026. Ovid has received a 'Strong Buy' rating on Wall Street because of its rich pipeline of rare disease treatments. The stock may appeal to long-term aggressive investors who are comfortable with volatility and have a strong interest in innovative science. However, I believe investors should wait until Ovid either clears the $1 delisting threshold or proves its clinical strategy with positive results. Analysts have an average target price of $2.88 for the stock, which implies upside potential of 860% from current levels. The Street-high price estimate stands at $4 for OVID stock. With a market cap of $609 million, Nuvation Bio is a clinical-stage biotech company that develops targeted oncology treatments for challenging cancers with limited treatment options. However, it may soon release a revenue-generating product to the market this year. NUVB stock is down 27.7% YTD, compared to the overall market gain. Nuvation Bio's pipeline includes programs addressing a variety of oncology targets, including breast, ovarian, and lung cancer. Its pipeline currently consists of four core programs: taletrectinib (ROS1 inhibitor), NUV-1511 (drug-drug conjugate), safusidenib (brain-penetrant IDH1 inhibitor), and NUV-868 (BET inhibitor). Taletrectinib, Nuvation's lead candidate for the treatment of ROS1+ and advanced non-small cell lung cancer, has already been approved in China and the United States. The company hopes to begin commercializing taletrectinib in mid-2025. In March, the firm secured $250 million in non-dilutive financing from Sagard Healthcare Partners, as well as $150 million in royalty financing and $50 million in debt, subject to approval. Nuvation also has the option to secure an additional $50 million in debt until June 30, 2026 if it completes its first commercial sale in the United States. Safusidenib is currently in Phase 2 trials, and NUV-1511 is in Phase ½ trials. The company intends to provide updates for both during the second half of 2025. Nuvation ended Q1 with $461.7 million in cash, cash equivalents, and marketable securities. A favorable FDA decision could open up significant market opportunities for the company. Nuvation Bio's late-stage pipeline, strong cash position, and clear commercialization path make it an appealing biotech growth stock to buy right now. However, the company's ability to generate profits after commercialization may take years, making it an appropriate choice for those with a high risk tolerance and a longer investment horizon. Overall, Wall Street rates NUVB stock a 'Strong Buy.' Of the seven analysts covering the stock, six rate Nuvation as a 'Strong Buy' while one recommends a 'Moderate Buy" rating. The average price target of $7.17 suggests that NUVB stock could rally around 258% over the next 12 months. The high price estimate of $10 suggests a gain of 400% over current levels. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
